Cas:33399-46-1 4-ethoxypyridine manufacturer & supplier

We serve Chemical Name:4-ethoxypyridine CAS:33399-46-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-ethoxypyridine

Chemical Name:4-ethoxypyridine
CAS.NO:33399-46-1
Synonyms:Pyridine,4-ethoxy;MFCD00973627;4-Ethoxy-pyridin;4-Ethoxy-pyridine;4-Aethoxy-pyridin
Molecular Formula:C7H9NO
Molecular Weight:123.15200
HS Code:2933399090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:188.2ºC at 760 mmHg
Density:0.999 g/cm3
Index of Refraction:1.49
PSA:22.12000
Exact Mass:123.06800
LogP:1.48030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Pyridine,4-ethoxy chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Aethoxy-pyridin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyridine,4-ethoxy Use and application,4-Aethoxy-pyridin technical grade,usp/ep/jp grade.


Related News: Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 4-ethoxypyridine manufacturer China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. 4-ethoxypyridine supplier Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’. 4-ethoxypyridine vendor The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 4-ethoxypyridine factory Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent).